Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40BBS | ISIN: US2498454055 | Ticker-Symbol:
NASDAQ
24.06.25 | 21:45
0,622 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
DERMATA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DERMATA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DERMATA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.06.Dermata Therapeutics, Inc. - 8-K, Current Report2
21.05.Dermata Therapeutics, Inc. - 8-K, Current Report1
14.05.Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results242- Dermata announced positive topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -- Dermata entered into a Clinical...
► Artikel lesen
14.05.Dermata Therapeutics, Inc. - 8-K, Current Report5
14.05.Dermata Therapeutics, Inc. - 10-Q, Quarterly Report2
15.04.Dermata Therapeutics files to sell 10.01M shares of common stock for holders1
15.04.Dermata meldet frühen Erfolg bei Aknebehandlung mit XYNGARI3
15.04.Dermata reports early success in acne treatment with XYNGARI2
DERMATA THERAPEUTICS Aktie jetzt für 0€ handeln
15.04.Dermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks279- Dermata previously announced XYNGARI produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial -- Additional data analysis revealed that XYNGARI...
► Artikel lesen
15.04.Dermata Therapeutics, Inc. - 8-K, Current Report2
28.03.Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules451SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of...
► Artikel lesen
27.03.Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne2
27.03.Dermata Therapeutics, Inc.: BREAKING: Dermata's XYNGARI Phase 3 Trial Topline Data Meets All Primary Endpoints197- XYNGARI achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI is the first once-weekly...
► Artikel lesen
27.03.Dermata shares rise on positive acne treatment trial results1
25.03.Dermata Therapeutics, Inc. - 8-K, Current Report3
17.03.Dermata Therapeutics Provides Corporate Update and Reports Year End 2024 Financial Results311- Dermata expects to announce topline results from its XYNGARI Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -- The Company recently entered into a Clinical...
► Artikel lesen
17.03.Dermata Therapeutics, Inc. - 8-K, Current Report2
17.03.Dermata Therapeutics, Inc. - 10-K, Annual Report4
04.03.Dermata Therapeutics, Inc.: Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI Phase 3 STAR-1 Clinical Trial for Acne141- STAR-1 topline results expected by the end of March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - XYNGARI Phase 3 STAR-1 trial...
► Artikel lesen
25.02.Dermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis597- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial...
► Artikel lesen
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1